

Semi-quantitative analysis of $\hat{I}\pm$ -synuclein in subcellular immunogold electron microscopic study using a C-term

Brain Research

1244, 40-52

DOI: [10.1016/j.brainres.2008.08.067](https://doi.org/10.1016/j.brainres.2008.08.067)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Optical Reporters for the Conformation of α -Synuclein Reveal a Specific Interaction with Mitochondria. <i>Journal of Neuroscience</i> , 2008, 28, 12305-12317.	1.7	185
2	Unique copper-induced oligomers mediate α -synuclein toxicity. <i>FASEB Journal</i> , 2009, 23, 2384-2393.	0.2	129
3	Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. <i>Experimental Neurology</i> , 2009, 218, 235-246.	2.0	279
4	α -Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. <i>Neuroscience Letters</i> , 2009, 454, 187-192.	1.0	174
5	Domain Δ of protein disulfide isomerase plays key role in inhibiting α -synuclein fibril formation. <i>Cell Stress and Chaperones</i> , 2010, 15, 415-421.	1.2	35
6	Copper binding regulates intracellular α -synuclein localisation, aggregation and toxicity. <i>Journal of Neurochemistry</i> , 2010, 113, 704-714.	2.1	104
7	Overexpression of α -synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. <i>Journal of Neurochemistry</i> , 2010, 114, 1007-1018.	2.1	27
8	DNA induced folding/fibrillation of α -synuclein: new insights in Parkinson's disease. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 418.	3.0	41
9	The Transgenic Overexpression of α -Synuclein and Not Its Related Pathology Associates with Complex I Inhibition. <i>Journal of Biological Chemistry</i> , 2010, 285, 7334-7343.	1.6	96
10	The regulation of synaptic function by α -synuclein. <i>Communicative and Integrative Biology</i> , 2010, 3, 106-109.	0.6	110
11	Mitochondrial trafficking of APP and α -synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 11-19.	1.8	127
12	Mitochondrial dysfunction in Parkinson's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 29-44.	1.8	481
13	Mitochondrial Fission-Fusion and Parkinson's Disease: A Dynamic Question of Compensatory Networks. , 2011, , 197-213.		1
14	α -Synuclein overexpression impairs mitochondrial function by associating with adenylate translocator. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 732-741.	1.2	54
15	Different sub-cellular localization of α -synuclein in the C57BLJ mouse's central nervous system by two novel monoclonal antibodies. <i>Journal of Chemical Neuroanatomy</i> , 2011, 41, 97-110.	1.0	45
16	Spinal cord and parkinsonism: Neuromorphological evidences in humans and experimental studies. <i>Journal of Chemical Neuroanatomy</i> , 2011, 42, 327-340.	1.0	14
17	Determining nuclear localization of α -synuclein in mouse brains. <i>Neuroscience</i> , 2011, 199, 318-332.	1.1	31
18	Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an α -Synuclein Based Rat Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2011, 1, 373-387.	1.5	61

#	ARTICLE	IF	CITATIONS
19	Pathological roles of α -synuclein in neurological disorders. <i>Lancet Neurology</i> , The, 2011, 10, 1015-1025.	4.9	328
20	Silencing of PINK1 induces mitophagy via mitochondrial permeability transition in dopaminergic MN9D cells. <i>Brain Research</i> , 2011, 1394, 1-13.	1.1	45
21	α -Synuclein Negatively Regulates Protein Kinase C δ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity. <i>Journal of Neuroscience</i> , 2011, 31, 2035-2051.	1.7	136
22	Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α -Synuclein. <i>Journal of Biological Chemistry</i> , 2011, 286, 20710-20726.	1.6	499
23	New evidence on α -synuclein and Tau binding to conformation and sequence specific GCFN α 1 rich DNA: Relevance to neurological disorders. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2012, 4, 112.	0.2	44
24	Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. <i>EMBO Journal</i> , 2012, 31, 3038-3062.	3.5	487
25	Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease. <i>Antioxidants and Redox Signaling</i> , 2012, 16, 896-919.	2.5	77
26	Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease. <i>Brain Research</i> , 2012, 1432, 95-113.	1.1	39
27	The role of α -synuclein in neurodegeneration " An update. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	16
28	Exercise partly reverses the effect of maternal separation on hippocampal proteins in α -hydroxydopamine-lesioned rat brain. <i>Experimental Physiology</i> , 2013, 98, 233-244.	0.9	28
29	Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013, 1828, 2532-2543.	1.4	120
30	The many faces of α -synuclein: from structure and toxicity to therapeutic target. <i>Nature Reviews Neuroscience</i> , 2013, 14, 38-48.	4.9	1,322
31	The role of α -synuclein in the pathophysiology of alcoholism. <i>Neurochemistry International</i> , 2013, 63, 154-162.	1.9	16
32	α -Synuclein and Mitochondrial Dysfunction in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2013, 47, 587-597.	1.9	120
33	Mitochondrial dysfunction and oxidative stress in Parkinson's disease. <i>Progress in Neurobiology</i> , 2013, 106-107, 17-32.	2.8	572
34	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. <i>Journal of Parkinson's Disease</i> , 2013, 3, 415-459.	1.5	68
35	The Role of Oxidative Stress in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 461-491.	1.5	1,218
36	TOM40 Mediates Mitochondrial Dysfunction Induced by α -Synuclein Accumulation in Parkinson's Disease. <i>PLoS ONE</i> , 2013, 8, e62277.	1.1	133

#	ARTICLE	IF	CITATIONS
37	Alpha-Synuclein Function and Dysfunction on Cellular Membranes. <i>Experimental Neurobiology</i> , 2014, 23, 292-313.	0.7	179
38	In vitro aggregation assays for the characterization of $\hat{\pm}$ -synuclein prion-like properties. <i>Prion</i> , 2014, 8, 19-32.	0.9	66
39	$\hat{\pm}$ -Opioid receptor activation reduces $\hat{\pm}$ -synuclein overexpression and oligomer formation induced by MPP+ and/or hypoxia. <i>Experimental Neurology</i> , 2014, 255, 127-136.	2.0	42
40	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <i>Biochemical Pharmacology</i> , 2014, 88, 508-516.	2.0	196
41	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of $\hat{\pm}$ -synuclein, and enhances its secretion and nuclear localization in cells. <i>Human Molecular Genetics</i> , 2014, 23, 4491-4509.	1.4	194
42	Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. <i>Neurobiology of Disease</i> , 2014, 70, 204-213.	2.1	87
44	Localization of $\hat{\pm}$ -synuclein in Teleost Central Nervous System: Immunohistochemical and Western Blot Evidence by 3D5 Monoclonal Antibody in the Common Carp, <i>Cyprinus carpio</i> . <i>Journal of Comparative Neurology</i> , 2015, 523, 1095-1124.	0.9	9
46	Novel subcellular localization for $\hat{\pm}$ -synuclein: possible functional consequences. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 17.	0.9	45
47	The phosphorylation of $\hat{\pm}$ -synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. <i>Journal of Neurochemistry</i> , 2015, 135, 4-18.	2.1	66
48	Familial Parkinson Disease-associated Mutations Alter the Site-specific Microenvironment and Dynamics of $\hat{\pm}$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2015, 290, 7804-7822.	1.6	44
49	Structure based aggregation studies reveal the presence of helix-rich intermediate during $\hat{\pm}$ -Synuclein aggregation. <i>Scientific Reports</i> , 2015, 5, 9228.	1.6	172
50	Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2015, 27, 6-9.	0.9	23
51	Intracellular Dynamics of Synucleins. <i>International Review of Cell and Molecular Biology</i> , 2015, 320, 103-169.	1.6	66
52	Neuronal hemoglobin in mitochondria is reduced by forming a complex with $\hat{\pm}$ -synuclein in aging monkey brains. <i>Oncotarget</i> , 2016, 7, 7441-7454.	0.8	23
53	What can trigger the onset of Parkinson's disease – A modeling study based on a compartmental model of $\hat{\pm}$ -synuclein transport and aggregation in neurons. <i>Mathematical Biosciences</i> , 2016, 278, 22-29.	0.9	19
54	Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. <i>Journal of Neurochemistry</i> , 2016, 139, 240-255.	2.1	163
55	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. , 2016, , .		10
56	Copper(I) Forms a Redox-Stable 1:2 Complex with $\hat{\pm}$ -Synuclein N-Terminal Peptide in a Membrane-Like Environment. <i>Inorganic Chemistry</i> , 2016, 55, 6100-6106.	1.9	23

#	ARTICLE	IF	CITATIONS
57	Chromatin-Bound Oxidized α -Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, S133-S150.	1.2	62
58	Mitochondrial-Associated Membranes in Parkinson's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 997, 157-169.	0.8	26
59	Mitochondrial dynamics in Parkinson's disease: a role for α -synuclein?. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 1075-1087.	1.2	134
60	α -Synuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 5042.	1.6	77
61	α -synuclein aggregation and its modulation. <i>International Journal of Biological Macromolecules</i> , 2017, 100, 37-54.	3.6	106
62	Effect of Alcohol on the Regulation of α -Synuclein in the Human Brain. , 2017, , 67-73.		1
63	Mitochondrial Fission and Fusion. , 2017, , 77-111.		5
64	Computational Analysis of Cholesterol Binding and Pore-Lining Regions in Alpha-Synuclein: Role in Mitochondrial Function. , 2017, 7, .		0
65	Impact of membrane curvature on amyloid aggregation. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2018, 1860, 1741-1764.	1.4	88
66	α -Synuclein nonhuman primate models of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 385-400.	1.4	27
67	Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3199.	1.8	45
68	Salidroside Promotes the Pathological α -Synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 377.	1.6	28
69	Mechanisms of α -Synuclein Induced Synaptopathy in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 80.	1.4	255
70	The Close Encounter Between Alpha-Synuclein and Mitochondria. <i>Frontiers in Neuroscience</i> , 2018, 12, 388.	1.4	99
71	Regulation of exocytosis and mitochondrial relocalization by Alpha-synuclein in a mammalian cell model. <i>Npj Parkinson's Disease</i> , 2019, 5, 12.	2.5	23
72	A split-GFP tool reveals differences in the sub-mitochondrial distribution of wt and mutant alpha-synuclein. <i>Cell Death and Disease</i> , 2019, 10, 857.	2.7	14
73	Glial <i>HMOX1</i> expression promotes central and peripheral α -synuclein dysregulation and pathogenicity in parkinsonian mice. <i>Glia</i> , 2019, 67, 1730-1744.	2.5	25
74	Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity. <i>Acta Neuropathologica</i> , 2019, 137, 939-960.	3.9	62

#	ARTICLE	IF	CITATIONS
75	Heterogeneity in α -synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 597-608.	1.8	27
76	Discrimination of pork/chicken adulteration in minced mutton by electronic taste system. <i>International Journal of Food Science and Technology</i> , 2019, 54, 670-678.	1.3	22
77	The unlikely partnership between $LRRK2$ and α -synuclein in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 339-363.	1.2	35
78	Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 483-498.	2.8	30
79	Engineered microtissue as an anatomically inspired model of Parkinson's disease. <i>Current Opinion in Biomedical Engineering</i> , 2020, 14, 75-83.	1.8	5
80	Hemoglobin- α -synuclein complex exhibited age-dependent alterations in the human striatum and peripheral RBCs. <i>Neuroscience Letters</i> , 2020, 736, 135274.	1.0	10
81	<i>Caenorhabditis elegans</i> as a model system for studying aging-associated neurodegenerative diseases. <i>Translational Medicine of Aging</i> , 2020, 4, 60-72.	0.6	27
82	Curcumin offsets PTZ-induced epilepsy: involving inhibition of apoptosis, wnt/β -catenin, and autophagy pathways. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2020, 7, 240-251.	0.2	2
83	Cytotoxicity and Mitochondrial Dysregulation Caused by α -Synuclein in <i>Dictyostelium discoideum</i> . <i>Cells</i> , 2020, 9, 2289.	1.8	10
84	Mechanisms of alpha-synuclein toxicity: An update and outlook. <i>Progress in Brain Research</i> , 2020, 252, 91-129.	0.9	49
85	The multifaceted role of mitochondria in the pathology of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021, 156, 715-752.	2.1	42
86	A method of purifying alpha-synuclein in <i>E. coli</i> without chromatography. <i>Heliyon</i> , 2021, 7, e05874.	1.4	5
88	Neurons and Glia Interplay in α -Synucleinopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4994.	1.8	28
89	The Association between α -Synuclein and α -Tubulin in Brain Synapses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9153.	1.8	10
90	Roles of α -synuclein in gastrointestinal microbiome dysbiosis-related Parkinson's disease progression (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19
91	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and α -Synucleinopathy. <i>Life</i> , 2021, 11, 938.	1.1	13
92	Role of α -synuclein in neurodegeneration: implications for the pathogenesis of Parkinson's disease. <i>Essays in Biochemistry</i> , 2014, 56, 125-135.	2.1	9
93	C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α -Synuclein in a Yeast Model of Parkinson's Disease. <i>PLoS Genetics</i> , 2016, 12, e1006098.	1.5	49

#	ARTICLE	IF	CITATIONS
95	Alpha-synuclein truncation and disease. <i>Health</i> , 2012, 04, 1167-1177.	0.1	6
96	Targeting α -Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson's Disease Therapy. , 0, , .		0
97	Ion-Catalyzed Reactive Oxygen Species in Sporadic Models of Parkinson's Disease. , 2016, , 75-113.		0
98	Mitochondrial Function and Neurodegenerative Diseases. , 2018, , 369-414.		1
100	T cells, α -synuclein and Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2022, 184, 439-455.	1.0	8
101	The mouse nicotinamide mononucleotide adenylyltransferase chaperones diverse pathological amyloid client proteins. <i>Journal of Biological Chemistry</i> , 2022, 298, 101912.	1.6	1
102	Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using <i>Caenorhabditis elegans</i> . <i>Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology</i> , 2022, 267, 111166.	0.8	2
104	Could Amyloid- β 1-42 or α -Synuclein Interact Directly with Mitochondrial DNA? A Hypothesis. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2803-2812.	1.7	3
105	Nuclear localization of alpha-synuclein affects the cognitive and motor behavior of mice by inducing DNA damage and abnormal cell cycle of hippocampal neurons. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	6
106	Research progress in traditional Chinese medicine in the treatment of Alzheimer's disease and related dementias. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
107	Intracellular Accumulation of α -Synuclein Aggregates Promotes S-Nitrosylation of MAP1A Leading to Decreased NMDAR-Evoked Calcium Influx and Loss of Mature Synaptic Spines. <i>Journal of Neuroscience</i> , 0, , JN-RM-0074-22.	1.7	0
108	Decreased serum levels of α -synuclein in patients with schizophrenia and their unaffected siblings. <i>Microbial Biotechnology</i> , 2023, 17, 1079-1086.	0.9	2
109	Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7221.	1.8	2